Literature DB >> 28454415

STAT3 activation and risk of recurrence in meningiomas.

Mahlon Johnson1, Mary O'Connell1, Kevin Walter2.   

Abstract

Several studies have suggested that activation of signal transducer and activator of transcription 3 (STAT3) is associated with initiation, progression and metastasis of numerous types of malignancy. However, the role of the Janus kinase-interleukin 6-STAT3 signaling pathway in the pathogenesis and recurrence of meningiomas is unknown. The present study evaluated STAT3 activation by western blotting and immunohistochemistry and assessed its association with Ki-67 labeling in 13 cases of meningioma in which frozen tissue and ≥5.5-year follow-up information were available, and in formalin-fixed meningioma tissues from 14 cases with an 8.4-year follow-up. The results of the western blot analysis indicated that STAT3 phosphorylation was markedly higher in grade II meningiomas compared with that in grade I, with mean densitometric values of 8.6 and 1.7 following normalization to actin, respectively. High STAT3 phosphorylation/activation was identified in 2 of 3 recurrent World Health Organization (WHO) grade I meningiomas and 0 of 3 non-recurrent meningiomas. Strong STAT3 phosphorylation/activation signal was also found in 2 of 4 recurrent grade II meningiomas and 1 of 3 non-recurrent cases. According to the immunohistochemistry results, phospho-STAT3 was not increased in WHO grade II tumors compared with that in grade I tumors, and was not significantly different between recurrent and non-recurrent cases. Ki-67 labeling was significantly increased in grade II vs. grade I tumors, and was also significantly increased in recurrent compared with non-recurrent grade I meningiomas. The results of the current study suggest that, while detection of phosphorylated/activated STAT3 may be useful in isolated cases, identifying activation may be of little value in predicting recurrence.

Entities:  

Keywords:  Ki-67; meningioma progression; meningioma recurrence; meningiomas; phosphorylated signal transducer and activator of transcription 3

Year:  2017        PMID: 28454415      PMCID: PMC5403594          DOI: 10.3892/ol.2017.5736

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  D SIMPSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-02       Impact factor: 10.154

2.  Expression and activation of epidermal growth factor receptors in meningiomas.

Authors:  R S Carroll; P M Black; J Zhang; M Kirsch; I Percec; N Lau; A Guha
Journal:  J Neurosurg       Date:  1997-08       Impact factor: 5.115

3.  Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.

Authors:  Christian Mawrin; Tina Sasse; Elmar Kirches; Siegfried Kropf; Thomas Schneider; Christoph Grimm; Claudia Pambor; Christian K Vorwerk; Raimund Firsching; Uwe Lendeckel; Knut Dietzmann
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

4.  Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells.

Authors:  Mahlon D Johnson; Evelyn Okedli; Ann Woodard; Steven A Toms; George S Allen
Journal:  J Neurosurg       Date:  2002-09       Impact factor: 5.115

5.  Computer system for cell counting in selected brain tumors at Ki-67 immunohistochemical staining.

Authors:  Tomasz Markiewicz; Bartlomiej Grala; Wojciech Kozlowski; Stanislaw Osowski
Journal:  Anal Quant Cytol Histol       Date:  2010-12       Impact factor: 0.302

6.  Meningioma grading: an analysis of histologic parameters.

Authors:  A Perry; S L Stafford; B W Scheithauer; V J Suman; C M Lohse
Journal:  Am J Surg Pathol       Date:  1997-12       Impact factor: 6.394

Review 7.  Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?

Authors:  Mahlon Johnson; Steven Toms
Journal:  J Neuropathol Exp Neurol       Date:  2005-12       Impact factor: 3.685

8.  Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time.

Authors:  Maria Vassilakopoulou; Fabio Parisi; Summar Siddiqui; Allison M England; Elizabeth R Zarella; Valsamo Anagnostou; Yuval Kluger; David G Hicks; David L Rimm; Veronique M Neumeister
Journal:  Lab Invest       Date:  2014-11-24       Impact factor: 5.662

Review 9.  The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.

Authors:  Winward Choy; Won Kim; Daniel Nagasawa; Stephanie Stramotas; Andrew Yew; Quinton Gopen; Andrew T Parsa; Isaac Yang
Journal:  Neurosurg Focus       Date:  2011-05       Impact factor: 4.047

Review 10.  Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy.

Authors:  Doris Germain; David A Frank
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

View more
  2 in total

1.  Systematic analysis of gene expression alterations and clinical outcomes of STAT3 in cancer.

Authors:  Xiangrong Cui; Xuan Jing; Qin Yi; Chunlan Long; Bin Tan; Xin Li; Xueni Chen; Yue Huang; Zhongping Xiang; Jie Tian; Jing Zhu
Journal:  Oncotarget       Date:  2017-12-14

2.  Identification of Meningioma Patients at High Risk of Tumor Recurrence Using MicroRNA Profiling.

Authors:  Hanus Slavik; Vladimir Balik; Jana Vrbkova; Alona Rehulkova; Miroslav Vaverka; Lumir Hrabalek; Jiri Ehrmann; Monika Vidlarova; Sona Gurska; Marian Hajduch; Josef Srovnal
Journal:  Neurosurgery       Date:  2020-10-15       Impact factor: 4.654

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.